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Arterial Disease in Patients With Human
Immunodeﬁciency Virus Infection
What Has Imaging Taught Us?
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Madison, Wisconsin; and Los Angeles and San Francisco, CaliforniaWith advances in antiretroviral therapy (ART), individuals with human immunodeﬁciency virus (HIV)
infection are living longer and increasingly die of non–HIV-related diseases, such as cardiovascular
disease (CVD). Several observational studies suggest that HIV-infected patients on ART are at
increased risk of CVD; however, the precise mechanisms underlying the association between
HIV infection and CVD risk are uncertain. Atherosclerosis and arterial disease in HIV-infected
individuals is a multifactorial process with several potential targets for research and therapeutic
intervention. This paper critically reviews the contributions of imaging to our understanding of
arterial disease, atherosclerosis, and CVD risk in HIV-infected individuals. In general, the ﬁndings
of studies using carotid ultrasound, coronary computed tomographic angiography, and aortic
positron emission tomography agree with those from observational studies of CVD events and
suggest that HIV infection is associated with an increased risk of CVD. Observational studies of
CVD outcomes and studies using carotid intima-media thickness suggest that there is a moderate
increase in CVD risk related to HIV serostatus. Less can be said about the role of ART and speciﬁc
ART therapies in CVD risk, mainly because imaging studies have had serious methodological
limitations that diminish their generalizability. Brachial artery reactivity testing has been especially
useful for elucidating the arterial pathophysiology of HIV infection and its treatments, as well as
the arterial effects of interventions for treating HIV and dyslipidemia. Aortic positron emission
tomography has been especially useful for evaluating arterial inﬂammation. Coronary artery
calcium has not proven to be a useful marker of subclinical atherosclerosis in HIV-infected
individuals. Imaging studies support the intriguing hypothesis that persistent inﬂammation and
immune dysregulation contribute to increased CVD risk among treated and suppressed patients
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516With the advent of potent combination antiretro-
viral therapy (ART), patients with human immu-
nodeﬁciency virus (HIV) infection are living longer
and increasingly are afﬂicted with chronic diseases
that are common among individuals without HIV
infection, such as cardiovascular disease (CVD),
cancer, liver disease, and lung disease (1,2). Among
HIV-infected individuals in the United States,
CVD is the leading non–HIV-related cause of
death, although in Europe, CVD death follows
cancer and liver disease among the leading causes
of mortality in this patient population (1,2). Several
observational studies suggest that HIV-infected
patients on ART are at increased CVD risk (3–8);
however, the precise mechanisms underlying the
association between HIV infection and CVD risk
are uncertain (8,9). This paper critically reviews thee
y
ctivity
ium
phy
se
iency
esscontributions of imaging to our current
understanding of arterial disease, athero-
sclerosis, and CVD risk in HIV-infected
individuals.
HIV and CVD Risk
Some of the increased CVD risk associ-
ated with HIV infection is due to an
increased burden of traditional risk factors
such as cigarette smoking, which is 2 to 3
times more prevalent in individuals with
HIV infection (10,11), and risk factors
related to use of protease inhibitors, such
as dyslipidemia and insulin resistance (11).
In the Data Collection on Adverse Events
of Anti-HIV Drugs study, exposure to
protease inhibitors was an independent
predictor of myocardial infarction (MI);
however, the major predictors were es-tablished CVD, current or former smoking, and
male sex, as well as increasing age and a family
history of heart disease (12). In fully-adjusted
models, diabetes mellitus, higher total cholesterol,
and lower high-density lipoprotein cholesterol levels
also were independent predictors of MI (12). In a
recent observational study from the Veterans Aging
StudyVirtual Cohort,HIV-infected veterans (mostly
men) had nearly a 50% increased relative risk of
acute MI compared with those without HIV, after
adjustment for traditional risk factors. In addition
to HIV serostatus, other independent risk factors
for incident MI were increasing age, hypertension,
increasing low-density lipoprotein cholesterol, ciga-
rette smoking, and renal disease (8). Thus, as in
HIV-uninfected individuals, traditional risk factors
powerfully predict CVD in those withHIV infection.However, hepatitis C coinfection, anemia, low
CD4þ T-cell counts, and high HIV-1 ribonucleic
acid (RNA) levels also predicted MI risk, suggesting
that certain characteristics of individuals with HIV
infection, in addition to traditional risk factors, may
contribute to increased CVD risk (8). Certain pro-
tease inhibitors, such as lopinavir/ritonavir, indinavir,
and amprenavir/fosamprenavir, have been associated
with increasedMI risk and certain nucleoside reverse
transcriptase inhibitors, most notably abacavir and
possibly didanosine, also may increase MI risk,
although data are conﬂicting (13–15). The impacts of
newer classes of antiretroviral agents such as CCR5
inhibitors and integrase inhibitors, which appear to
have fewer lipid effects on CVD risk, are largely
unknown at this time.
Although the use of ART has been associated
with increased CVD risk, 1 large observational
study demonstrated that HIV treatment did not
increase short-term CVD risk (16). A growing
body of evidence suggests that persistent inﬂamma-
tion and disordered immune regulationd
which are present even among effectively-treated
HIV-infected individualsdmay increase CVD risk
(17). In an observational study, the odds ratio for
acute MI was >4-fold higher among patients with
HIV and elevated C-reactive protein compared
with those without HIV and with normal C-reactive
protein (18). In the SMART (Strategies for Man-
agement of Anti-Retroviral Therapy) study, inter-
ruption of ART in individuals with chronic
HIV infection was associated with high levels of
interleukin-6 and D-dimers, biomarkers that were
associated independently with all-causemortality and
CVD events; furthermore, ART initiation at higher
CD4þ T-cell counts reduced serious non–acquired
immunodeﬁciency syndrome (AIDS) events, which
were mostly due to CVD, in a subset of participants
who were ART-naive or had not been receiving ART
for at least 6 months before participation (19,20).
Indeed, although inﬂammation and immune dys-
regulation play key roles in accelerating atheroscle-
rosis in individuals without HIV (21,22), the causes
of ongoing inﬂammation and immune dysregula-
tion in individuals with treated HIV infection
appear to be more complicated than in individuals
without HIV, whose inﬂammation is driven, in
large part, by visceral adiposity and the metabolic
syndrome (17). Atherosclerosis and arterial disease
in HIV-infected individuals clearly is a multifac-
torial process (Fig. 1) with several potential targets
for research and therapeutic intervention.
The extent by which HIV infection increases
CVD risk beyond traditional risk factors and the
Figure 1. Factors Contributing to Atherosclerosis and Arterial Injury in
HIV-Infected Individuals
Atherosclerosis and arterial disease in human immunodeﬁciency virus
(HIV)–infected individuals is a multifactorial process involving the virus,
antiretroviral therapy, traditional risk factors for cardiovascular disease and
genetic predisposition. Each arrow represents a potential target for research
and therapeutic intervention.
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517speciﬁc contributions of ART has been difﬁcult
to determine. Most of the current data suggesting
increased CVD risk among HIV-infected patients
comes from observational studies that were not
designed to evaluate CV endpoints and thus have
important methodological limitations, including
short duration of follow-up, low overall event rates,
incomplete ascertainment of CVD risk factors and
events, and lack of proper HIV-negative control
groups. Furthermore, most HIV-infected patients
are relatively young and are at low short-term CVD
risk, which limits the power of observational studies
to more accurately quantify CVD risk, especially in
the setting of traditional risk factors that may have
been present longer than HIV infection itself.
However, the weight of the evidence suggests that
there is a moderate degree of excess CVD risk due
to HIV infection, especially in individuals over 45 to
50 years of age (7,8).
To overcome some of these limitations, many
investigators have used arterial imaging to better
understand the magnitude and contributors to the
increased CVD risk associated with HIV infection
and its mechanisms. The dominant imaging tech-
nologies have been carotid ultrasound (to measure
intima-media thickness [IMT] and to assess for
plaque presence), cardiac computed tomography
(to measure coronary artery calcium [CAC] or for
computed tomography angiography [CTA] to
assess coronary plaque burden and composition),
brachial artery ultrasound (for brachial arterial
reactivity testing [BART], a measure of endothelial
function), and more recently, positron image to-
mography (PET) (to assess arterial inﬂammation).
Collectively, studies using these imaging technolo-
gies support the observational evidence that HIV
infection is associated with increased CVD risk.
These imaging modalities have elucidated new
pathways for investigating the pathophysiology of
arterial disease, atherosclerosis, and increased CVD
risk in patients with HIV infection.Carotid Ultrasound
Increased carotid IMT is associated with prevalent
CVD and risk factors as well as increased risk of
future MI and stroke (23–25). Carotid plaque
presence also is associated with an increased risk of
future CVD events, independent of traditional risk
factors (23,26). Longitudinal carotid IMT pro-
gression also has been used as a surrogate marker of
change in CVD risk associated with lipid-lowering
and antihypertensive medications; however, itsassociation with changes in CVD risk in the general
population is less clear (27–29).
Over 20 observational studies have measured ca-
rotid IMT in individuals with HIV (30). Several
also assessed for the presence of carotid plaques. In
a meta-analysis that included most of these studies,
the carotid IMT of individuals with HIV infection
was, on average, 0.04 mm thicker (95% conﬁdence
interval: 0.02 to 0.06 mm, p < 0.001) than that of
individuals without HIV infection (Fig. 2) (30).
This difference in carotid IMT is of a magnitude
that is consistent with the observational studies
showing increased CVD risk in individuals with
HIV infection. However, the studies included in the
meta-analysis had widely varying population char-
acteristics, study designs, sample sizes, and length of
follow-up, and different ultrasound techniques.
Most of these studies measured common carotid
artery IMT, although some measured IMT in the
bifurcation and/or internal carotid artery segments.
The ﬁnding of higher carotid IMT among those
with HIV had signiﬁcant heterogeneity between
studies (I2 ¼ 86.5%), evidence for publication bias
(p ¼ 0.001), confounding by male sex, and residual
confounding, because a larger effect size was
observed among studies with the greatest between-
group demographic differences (30). Smaller
studies were more likely to conclude that HIV-
infected patients had thicker carotid IMT; the
point estimates from larger studies were clustered
around no effect. Nevertheless, a subsequent report
from the cohort with the second largest number of
Figure 2. Differences in Carotid IMT by HIV Serostatus
Meta-analysis of 13 studies evaluating the associations between human
immunodeﬁciency virus (HIV) serostatus and carotid intima-media thickness
(IMT). The carotid IMT of individuals with HIV infection was, on average,
0.04 mm thicker (95% conﬁdence interval [CI]: 0.02 to 0.06 mm, p < 0.001) than
that of individuals without HIV infection. Reprinted, with permission, from
Hulten et al. (30). WMD ¼ weighted mean difference.
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meta-analysis (31). In the FRAM (Study of Fat
Redistribution and Metabolic Change), the mean
difference in common carotid artery IMT between
HIV-infected and uninfected control patients was
0.033 mm (p ¼ 0.005) after adjustment for de-
mographic and traditional CVD risk factors (31).
In addition to HIV infection, these investigators
also demonstrated independent effects of traditional
CVD risk factors such as age, male sex, current and
past smoking, diabetes mellitus, blood pressure, and
total and high-density lipoprotein cholesterol on
carotid IMT (31). Of note, directionally similar
but larger effects were observed in the internal ca-
rotid artery than in the common carotid artery (31).
The meta-analysis did not ﬁnd higher carotid IMT
for HIV-infected patients exposed to protease in-
hibitors, with a high degree of study heterogeneity
but no evidence of publication bias (30).
Among 6 studies, the odds ratio for carotid pla-
que presence in HIV-infected individuals compared
with uninfected control patients was 1.50 (p ¼
0.084, I2 ¼ 67%), with signiﬁcant heterogeneity
(I2 ¼ 67%, p ¼ 0.009). Carotid plaque tended to be
more prevalent in patients on protease inhibitors,
but the p value did not reach statistical signiﬁcance
(odds ratio [OR]: 1.71, p ¼ 0.103), possibly due
to heterogeneity (I2 ¼ 52%, p ¼ 0.059). Thus,
cross-sectional observational studies using carotid
ultrasound support the observational studies that
evaluated CVD events in demonstrating that: 1)traditional CVD risk factors are the primary asso-
ciates of arterial injury among patients with HIV;
and 2) a moderate independent association between
HIV serostatus and both increased carotid IMT and
plaque presence. However, it is not clear if there is
an association with use of protease inhibitors.
An even smaller number of studies have looked
at the effects of HIV on the longitudinal progres-
sion of carotid IMT. The meta-analysis only re-
viewed 3 small to moderate-sized studies that
evaluated change in carotid IMT over time (30).
These studies had differing conclusions: 1 described
a positive association between HIV serostatus and
carotid IMT progression (32), but 1 did not (33).
One study found that use of protease inhibitors
was associated with more rapid carotid IMT pro-
gression (32), but 2 did not (33,34). Each of these
studies had a markedly different study design and
participant characteristics. Although they broadly
agreed that traditional CVD risk factors predicted
progression of carotid IMT, they had differing con-
clusions in regard to the directionality and mag-
nitude of certain risk factors, including CD4 cell
count (30). Two subsequent, moderate-sized studies
of carotid IMT progression also had inconsistent
conclusions (35,36). In 1 study, slower carotid
IMT progression was observed among individuals
with a persistently-suppressed HIV RNA viral
load, but with faster progression among those taking
protease inhibitors compared with those taking non-
nucleoside reverse transcriptase inhibitor-based
regimens (35). Increased body mass index was the
only traditional CVD risk factor that independently
predicted carotid IMT progression (35). In a second
study, traditional CVD risk factors, but no HIV-
related measures, were associated with carotid
IMT progression; however, the speciﬁc risk factors
and the magnitude of their associations were in-
consistent between carotid artery segments (36). In
that study, waist circumference and markers of
insulin-glucose metabolism appeared to be the most
consistent predictors of carotid IMT progression,
but these ﬁndings have not been consistently dem-
onstrated (36). For example, another study showed
that the IMT progression occurs preferentially at
the carotid bifurcation region in HIV-infected in-
dividuals and is associated with levels of high-
sensitivity C-reactive protein (37). Increased
carotid IMT progression also has been observed
after initiation of ART (38) and with tenofovir-
based therapy (39,40). These studies, however, were
quite small.
In regard to inﬂammation and markers of im-
mune activation, the Women’s Interagency Health
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vation and senescence were associated with in-
creased carotid plaque prevalence (41). In some
studies of suppressed HIV-infected patients,
chronic inﬂammation has been associated with
increased carotid IMT (42,43), but not in others
(33,35), perhaps due to differing subject pop-
ulations and imaging approaches. Recently, el-
evated sCD14 levels have been associated with
increased carotid IMT progression in individuals
with HIV (44).
In summary, traditional CVD risk factors
consistently are associated with carotid IMT in
HIV-infected individuals. In agreement with ob-
servational studies describing CVD events, HIV
infection appears to be associated with higher ca-
rotid IMT of a magnitude that is broadly consistent
with the observational studies that show an in-
creased risk of CVD events in individuals with
HIV infection. However, the effects of HIV infec-
tion, its treatments, and its associated immunolog-
ical abnormalities on carotid IMT progression and
plaques are unclear.
Cardiac Computed Tomography: CAC and CTA
The presence and quantity of CAC are powerful,
independent predictors of CVD risk in the general
population (45–47). In 1 large epidemiological
study, the predictive value of CAC for incident
coronary heart disease and cerebrovascular disease
exceeded that for carotid IMT and brachial artery
ﬂow-mediated dilation (FMD) (48). The effects of
HIV serostatus on CAC were addressed in the same
paper that described a meta-analysis of carotid IMT
and HIV serostatus (30). Seven studies were
included in the CAC meta-analysis, including the
largest HIV experience, from the Multicenter AIDS
Cohort Study (30,49). In the 5 studies that com-
pared CAC among HIV-positive versus -negative
patients, the odds ratio for CAC was not sig-
niﬁcantly higher among HIV-infected patients
(OR: 0.95, p ¼ 0.851); however, signiﬁcant het-
erogeneity was noted (I2 ¼ 65%, p ¼ 0.024).
Similarly, the OR for CAC among the 3 studies
comparing HIV-infected patients with and without
protease inhibitor exposure also was not signiﬁcant
(p ¼ 0.506). In the Multicenter AIDS Cohort
Study cohort of 332 HIV-negative and 615 HIV-
positive men, the adjusted OR for CAC preva-
lence was 1.35; however, the 95% conﬁdence
interval was wide (0.7 to 2.61) and was similar in
regard to long-term use of ART, without evidence
of increased harm or beneﬁt by treatment (49).Subsequent observational studies have demon-
strated independent associations among CAC
and increasing age, hyperapobetalipoproteinemia,
C-reactive protein, and metabolic syndrome in HIV-
infected patients (50,51). Similarly, the Multicenter
AIDS Cohort Study also demonstrated that in-
creasing age was the strongest predictor of CAC
presence among HIV-infected and uninfected in-
dividuals (49). Another study reported that in
addition to traditional CVD risk factors (including
age), HIV serostatus and use of cocaine were asso-
ciated with CAC among African-Americans (52).
As most studies that measured CAC in HIV-
infected individuals had relatively young subjects
(mean age <50 years), they would be expected to
have low rates of CAC presence, because CAC is
a later ﬁnding in atherogenesis than is arterial wall
thickening. Accordingly, in a study that compared
CAC and carotid IMT in HIV-infected indi-
viduals, more than one-third of HIV patients with
undetectable CAC had markedly increased IMT,
suggesting that in young to middle-aged HIV-
infected patients, carotid IMT may be a more
sensitive indicator of subclinical vascular disease
than CAC (53).
CTA recently has shed signiﬁcant light on CVD
risk in patients with HIV infection, because it can
identify noncalciﬁed as well as calciﬁed plaque. In
a cross-sectional study of 114 HIV-positive and
40 HIV-negative men, CAC scores were higher
in those with metabolic syndrome, but CAC pres-
ence was not associated with HIV serostatus (54).
However, CTA identiﬁed a higher prevalence of
plaque in HIV-positive individuals due to an in-
creased prevalence of noncalciﬁed plaque segments
(54). The Multicenter AIDS Cohort Study described
the results of CTA in 343 HIV-infected and 176
HIV-negative men (Fig. 3) (55).
HIV positivity was associated independently with
the extent of noncalciﬁed plaque as well as diabetes
mellitus, hypertension, and dyslipidemia, and in-
dependent associations with coronary stenoses of
$50% were identiﬁed with CD4 nadir, use of ART
for >10 years, and detectable HIV RNA, even after
adjustment for traditional CVD risk factors (55).
Thus, an increased burden of noncalciﬁed plaque
identiﬁed by CTA appears to explain the weak and
inconsistent associations previously described be-
tween CAC and HIV serostatus. Another study
reported that among African-Americans with HIV
infection, coronary stenoses of $50% were inde-
pendently associated with traditional CVD risk
factors, long-term cocaine use ($15 years), and
exposure to ART for $6 months (56). In addition
Figure 3. Coronary Plaques Detected by Coronary Computed Tomography Angiography in the Multicenter AIDS Cohort Study
Examples of noncalciﬁed (left), mixed (middle), and calciﬁed (right) plaques detected by coronary artery computed tomography.
Reprinted, with permission, from Post et al. (55). AIDS ¼ acquired immunodeﬁciency syndrome.
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of cocaine, stavudine or lamivudine, and zidovudine
also have been identiﬁed as independent associates
of signiﬁcant coronary stenosis (52).
In summary, CAC alone appears to be an inad-
equate research tool for studying arterial disease
burden in young adults with HIV infection. Al-
though CAC is associated with traditional CVD
risk factors, it does not appear to identify HIV-
related CVD risk. Recent CTA ﬁndings consis-
tently demonstrate increased noncalciﬁed coronary
atherosclerosis among younger patients with HIV
infection in association with traditional risk factors
and HIV serostatus. The magnitude of increased
CVD risk associated with the increased prevalence
of noncalciﬁed coronary atherosclerosis remains
unclear because the studies cited in the previous text
were relatively small and observational, and some
only included women. CTA is a valuable research
tool for evaluating the causes and extent of sub-
clinical atherosclerosis among individuals with HIV
infection.
Brachial Artery Reactivity Testing
Brachial artery ultrasound can be used to assess
FMD, a marker of endothelial function that pre-
dicts future CVD risk (57,58). As a sensitive and
rapidly responsive biomarker, BART has played
an important role in assessing the arterial patho-
physiology of HIV infection and its treatments
on CVD risk. Studies using BART have con-
sistently demonstrated that patients with HIV in-
fection have endothelial dysfunction relative to
patients without HIV infection. In a case-control
study of children (mean age 11 years), brachial-artery FMD was signiﬁcantly lower in HIV-
infected patients compared with control patients
(p ¼ 0.02) and was worse among children treated
with protease inhibitors (p ¼ 0.05) (59). In chil-
dren, endothelial dysfunction was present even
after adjustment for baseline diameter and tradi-
tional CVD risk factors including C-reactive protein
(59). In adults, case-control studies evaluating the
effects of HIV infection on FMD have had incon-
sistent results (60–64). Each of these studies has
been relatively small, with the largest including only
83 HIV-infected individuals, and the population
characteristics as well as imaging techniques have
varied between studies (60–63). A wide range of risk
factors have been associated (albeit inconsistently)
with impaired FMD among patients with HIV,
including lipoprotein levels, HIV viral load, nadir
CD4 T-cell count, intravenous drug use, systolic
blood pressure, markers of insulin-glucose meta-
bolism, and presence of metabolic syndrome,
among others. Similarly, the relationship between
C-reactive protein and FMD in individuals with
HIV is uncertain. One study suggested that higher
C-reactive protein was associated with impaired
endothelial function in HIV-infected patients (65),
but 4 others did not (59,62,63,66). Each study had
<100 HIV infected subjects with varying demo-
graphic, CVD risk factor, andHIV treatment proﬁles.
In a prospective, randomized clinical trial of 82
ART-naive individuals (median age 35 years) ran-
domized to 3 treatment-sparing initial ART regi-
mens, FMD improved after both 4 and 24 weeks of
ART, with similar changes in all arms (Fig. 4) (66).
Change in FMD after 24 weeks of initiating
ART was inversely associated with change in HIV
RNA levels (p ¼ 0.017), despite an increase in
Figure 4. Effects of 3 Class-Sparing ART Regimens on
Changes in Brachial Artery FMD Over 24 Weeks
Thick bars indicate medians; box edges indicate 25th to 75th
percentiles; and error bars indicate 95% conﬁdence intervals.
Reprinted, with permission, from Torriani et al. (66). ART ¼ anti-
retroviral therapy; EFV ¼ efavirenz; FMD ¼ ﬂow-mediated vaso-
dilation; LPV/r ¼ lopinavir/ritonavir; NNRTI ¼ non-nucleoside
reverse transcriptase inhibitor; NRTI ¼ nucleoside reverse tran-
scriptase inhibitor; PI ¼ protease inhibitor.
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They suggest, as have others, that high viral load
causes endothelial dysfunction and that treatment
of viremia improves the endothelial dysfunction
associated with HIV infection (67). Collectively,
BART studies suggest that, in individuals with
HIV infection and active viral replication, the
beneﬁcial effects of ART outweigh the potential
adverse effects of speciﬁc drug classes or adverse
metabolic effects such as increases in lipids or
changes in insulin-glucose metabolism.
BART studies that evaluated the effects of HIV
protease inhibitors on FMD also have had mixed
results, likely due to small sample sizes, varying
subject characteristics, and different distributions
of traditional CVD risk factors (59,60,64,68).
However, 2 randomized studies using BART evalu-
ated the effects of switching patients from early
protease inhibitors to atazanavir, a protease inhibi-
tor with less adverse metabolic effects; they did not
show improvements in FMD despite improvements
in lipids (69,70). Another randomized trial did not
show improvement in FMD with raltegravir inten-
siﬁcation in ART-suppressed patients (71). However,
2 randomized studies demonstrated improvements
in endothelial function in dyslipidemic HIV-
infected patients who received statins (72,73).
Finally, observational data regarding the effects ofabacavir on FMD also have had divergent results.
A single-center study of 61 treated and suppressed
HIV-infected patients found that those taking
abacavir had lower FMD (74); however, a study of
148 individuals who initially were assigned ran-
domly to abacavir or tenofovir did not ﬁnd lower
FMD among those taking abacavir (75).
In summary, the results of BART studies suggest
that untreated HIV infection and traditional CVD
risk factors worsen FMD and that ART initiation
and treatment of dyslipidemia with statins improve
FMD. Switching patients off of protease inhibitors
or intensifying ART does not improve endothelial
function. Although ART initiation improves en-
dothelial function, FMD remains abnormal even in
the setting of treated and suppressed HIV infection.
The long-term effects of abacavir on endothelial
function remain unclear.
Imaging Arterial Inﬂammation With PET
A growing body of evidence suggests that, in
addition to traditional CVD risk factors such as
smoking, dyslipidemia, and components of the
metabolic syndrome, inﬂammation may play a key
role in increasing CVD risk among treated and
suppressed HIV-infected patients. An observa-
tional study of over 70,000 subjects (487 HIV
infected) demonstrated that elevated C-reactive
protein (OR: 2.13, p < 0.0001) and HIV infection
(OR: 1.93, p ¼ 0.004) were independently associ-
ated with acute MI (18). Furthermore, the SMART
study found that interruption of ART in chronic
HIV infection was associated with high levels of
interleukin-6 and D-dimers, that those biomarkers
were associated with all-cause mortality and CVD
events, and that ART initiation at higher CD4
positive T-cell counts reduced non-AIDS events,
which mostly were due to CVD (19,20). These
observations are supported by an observed im-
provement in brachial FMD with ART initiation
and its observed inverse association with HIV
RNA load (66), as well as the association of higher
markers of T-cell activation and senescence with
carotid plaque prevalence (41). Furthermore, more
rapid progression of carotid IMT has been associ-
ated with chronic inﬂammation in individuals with
HIV (42,43). Ultrasound and CT, however, are
unable to directly image inﬂammation.
18-ﬂuorodeoxyglucose (18FDG) uptake by arte-
rial macrophages can been used to image arterial
inﬂammation and early atheroma formation using
PET CT technology. In a proof-of-concept study,
when compared with 5 HIV-negative individuals, 9
Figure 5. 18FDG-PET/Computed Tomographic Aortic Imaging in HIV
Increased aortic positron emission tomography (PET) 18ﬂuorodeoxyglucose (FDG) uptake (red) in a human immunodeﬁciency virus
(HIV)–infected participant compared with a risk-factor matched control patient. Reprinted, with permission, from Subramanian et al. (77).
A ¼ anterior-posterior orientation; F ¼ foot-head orientation; FRS ¼ Framingham score; SVC ¼ superior vena cava; TBR ¼ target-to-
background ratio.
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on ART were shown to have higher 18FDG uptake
in the carotid arteries (76). In another cross-
sectional study, 27 HIV-infected individuals were
compared with 2 non–HIV-infected control
groups: 1 matched for age, sex, Framingham risk
score, and lack of atherosclerotic disease, and the
other matched on sex but with known atheroscle-
rotic disease (77). Aortic 18FDG PET uptake was
signiﬁcantly higher in individuals with HIV com-
pared with Framingham score-matched control
patients, even after adjusting for traditional CVD
risk factors (p ¼ 0.002) and in multiple subanalyses
(Fig. 5) (77).
Aortic 18FDG PET uptake was associated with
levels of sCD163 (p ¼ 0.04), a marker of monocyte
and macrophage activation that tracks levels of
HIV RNA and is associated with cellular markers
of immune activation (17,78). sCD163 levels also
have been associated with noncalciﬁed plaque, but
not with CAC, in ART-treated subjects withundetectable HIV viral loads compared with HIV-
negative control patients. However, markers of
more generalized information such as C-reactive
protein and D-dimers were not associated with
sCD163, coronary plaque, or 18FDG PET uptake
(78).
Conclusions
Arterial imaging is a useful tool for investigating
CVD risk among patients with HIV infection and
for exploring its causes. Carotid ultrasound, coro-
nary CT, brachial artery ultrasound, and more
recently, 18FDG PET have provided important
insights into the prevalence and pathophysiology of
HIV-associated CVD risk. In general, the ﬁndings
of studies using carotid ultrasound, coronary CT
angiography, and 18FDG PET agree with those
from observational studies of CVD events and
suggest that HIV infection is associated with an
increased risk of CVD. BART has been especially
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523useful for elucidating the arterial pathophysiology of
HIV infection and its treatments, as well as the
arterial effects of interventions for treating HIV and
dyslipidemia. 18FDG PET has been especially
useful for evaluating arterial inﬂammation. CAC
has not proven to be a useful marker of subclinical
atherosclerosis in HIV-infected individuals.
Observational studies of CVD outcomes and
studies using carotid IMT suggest that there is
a moderate increase in CVD risk related to HIV
serostatus. Less can be said about the role of ART
and speciﬁc ART therapies on CVD risk, mainly
because imaging studies have had serious meth-
odological limitations that diminish their general-
izability. Studies that have harnessed the power of
randomized clinical trials have been especially
powerful in clarifying the relationships between
ART and use of statins in HIV-infected patients.The identiﬁcation of improved endothelial function
with viral suppression and ART, of an excess of
noncalciﬁed coronary plaque in patients with HIV
infection, and of increased arterial inﬂammation in
suppressed HIV patients have opened up new
pathways for investigating the effects of persistent
inﬂammation and immune dysregulation on CVD
risk among ART-suppressed individuals. The
generalizability and impact of imaging studies in
HIV-infected patients will increase with greater use
of randomized clinical trial designs, with larger
studies with longer follow-up, and with improved
standardization of the imaging outcome measures.
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